Prescription-grade crystalline glucosamine sulfate as an add-on therapy to conventional treatments in erosive osteoarthritis of the hand: results from a 6-month observational retrospective study
| Autor: | Sara Tenti, Nicola Veronese, Sara Cheleschi, Iole Seccafico, Olivier Bruyère, Jean-Yves Reginster, Antonella Fioravanti |
|---|---|
| Přispěvatelé: | Tenti, Sara, Veronese, Nicola, Cheleschi, Sara, Seccafico, Iole, Bruyère, Olivier, Reginster, Jean-Yve, Fioravanti, Antonella |
| Rok vydání: | 2022 |
| Předmět: |
Aging
Glucosamine Symptomatic slow-acting drugs for osteoarthritis Pain Osteoarthritis Knee Prescription-grade crystalline glucosamine sulfate Erosive hand osteoarthritis Hand osteoarthritis Retrospective study Prescriptions Treatment Outcome Case-Control Studies Humans Erosive hand osteoarthritis Hand osteoarthritis Pain Prescription-grade crystalline glucosamine sulfate Retrospective study Symptomatic slow-acting drugs for osteoarthritis Geriatrics and Gerontology Retrospective Studies |
| Zdroj: | Aging clinical and experimental research. 34(7) |
| ISSN: | 1720-8319 |
| Popis: | Objective To evaluate the efficacy of prescription-grade Crystalline Glucosamine Sulfate (pCGS) as an add-on treatment to conventional therapy, compared to usual therapy alone, in patients with erosive osteoarthritis of the hand (EHOA). Methods This 6-month retrospective case–control study included patients with concomitant knee osteoarthritis and symptomatic EHOA. Participants were stratified into two groups based on whether or not pCGS (1500 mg/day) was added to the conventional therapy (education and training in ergonomic principles, exercise and use on-demand of symptomatic drugs) for hand osteoarthritis. Patients were evaluated at baseline, after 3 and 6 months. Primary outcomes were the change from baseline to month 6 in Visual Analogue Scale (VAS) hand pain and in Functional Index for Hand Osteoarthritis (FIHOA) score. A set of secondary parameters was also evaluated. Results 123 patients were included as follows: 67 treated with pCGS in addition to conventional therapy (pCGS Group) and 56 with conventional therapy alone (Control Group). After 6 months a significant difference in VAS and in FIHOA score (p p p p p p p Conclusions Despite all the limitations inherent to an observational study, our results suggest the potential effectiveness of pCGS, when used in combination with conventional therapy in EHOA. Further randomized placebo-controlled trials are needed to confirm these positive findings. Trial Registration ClinicalTrials.gov, http://www.clinicaltrials.gov, date of registration: February 2, 2022, NCT05237596. The present trial was retrospectively registered. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink